AnaptysBio, Inc. research snapshot
ANAB AI stock analysis now reads AnaptysBio as a royalty management company, not a clinical biotech. After the April 20, 2026 spin-off of First Tracks Biotherapeutics, AnaptysBio exclusively manages the financial collaborations for Jemperli (with GSK) and imsidolimab (with Vanda). Q1 2026 collaboration revenue was $25.56 million, including $24.7 million in Jemperli royalties up 44% year over year, with management guiding to an EBIT margin above 95% on a lean virtual operation. On a trailing twelve months basis revenue was about $232.4 million with a net loss of about $26.8 million and EPS of -$0.95, though this window still mixes in pre-spin First Tracks activity. Cash plus investments were about $286.5 million at March 31, 2026, against about $277.4 million in total debt, mostly a liability related to the sale of future royalties to Sagard. At the August 3, 2026 closing reference of $53.66 and about 29.6 million shares outstanding, the verified market cap was about $1.59 billion. This ANAB AI stock forecast is scenario-based, not a precise price prediction, and should be used as an informational research tool, not investment advice.
Current price
$53.66 closing reference on August 3, 2026
Market cap
$1.59 billion equity value
AI score
55 / 100
Rating
Royalty management company with two externally managed drug royalty streams (Jemperli with GSK, imsidolimab with Vanda), a high-margin virtual operating model, and concentrated revenue dependency
Trend status
Mixed trend after a 23% pullback from the mid-July high; price sits below the 50-day moving average and just above the 200-day moving average near $52.82
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | AnaptysBio now monetizes royalties from Jemperli (sold by GSK) and imsidolimab (developed by Vanda) under a virtual, high-margin operating model. Revenue quality improved after the spin-off, but the business earns from two externally controlled programs. | Medium |
| Moat | The economic moat is moderate and indirect: the Jemperli and imsidolimab royalties are protected by the partners commercial execution, the underlying patent positions, and long-dated collaboration agreements. AnaptysBio does not control the assets it earns from. | Low-medium |
| Management | CEO Daniel Faga executed the spin-off, kept operating expenses minimal, and added royalty-sector leaders Chris Murphy (CFO), Susannah Gray, and Owen Hughes to the team and board. The $100 million buyback plan shows capital return intent, though it is optional and expires December 31, 2026. | Medium |
| Financial trend | FY2025 revenue was about $234.6 million (up 157% year over year) with operating income turning positive at about $47.9 million, versus a $114.95 million operating loss in FY2024. TTM figures still mix in pre-spin activity. Cash fell about $25.1 million in Q1 2026 and the company is expected to reclassify First Tracks results as discontinued operations from Q2 2026. | Medium |
| Valuation | At $53.66, ANAB trades at about 6.8x trailing revenue and 30.1x forward earnings, with a high price-to-book ratio and minimal book value. EV of about $1.58 billion is roughly 44.8x EBITDA. The valuation prices in growing Jemperli royalties and imsidolimab approval rather than current GAAP earnings. | Medium |
| Technical trend | The stock rose about 117% over 52 weeks to a $73.30 high but pulled back to $53.66, about 23% below the mid-July high. Price is below the 50-day average near $57.59 and just above the 200-day average near $52.82, with an RSI near 44.5. | Medium |
| Risk level | High. Key risks are concentrated reliance on GSK Jemperli sales, imsidolimab approval risk with a December 12, 2026 PDUFA date, the Sagard royalty monetization structure, GSK litigation, optional and expiring buyback, high short interest near 17% of shares, and event-driven volatility. | Medium |
| AI confidence | Descriptive data confidence is medium-high because core data points were verified from StockAnalysis.com and the Q1 2026 press release, but forward royalty income, GSK execution, and approval timing are not publicly predictable. | Medium data confidence |
| Investment certainty | The royalty model is more transparent than the pre-spin clinical pipeline and analysts carry a Strong Buy consensus, but concentrated partner dependency and the Sagard structure keep investment certainty at low to medium. | Low-medium |
ANAB AI stock forecast
The ANAB AI stock forecast uses the August 3, 2026 closing reference of $53.66, the FY2025 revenue base of about $234.6 million, analyst forward estimates, and a royalty growth framework. Analyst consensus is Strong Buy with an average target of $87.09 and a range of $70 to $140. The bearish area assumes slower Jemperli growth or approval setbacks, the base case reflects steady royalty growth and Sagard paydown, and the bullish case assumes accelerating Jemperli royalties plus imsidolimab approval. These are scenario ranges, not promises.
$80 to $100
More likely if Jemperli keeps growing at a high double-digit rate, AZUR-1 and AZUR-4 readouts in the second half of 2026 are positive, imsidolimab wins approval at the December 2026 PDUFA date, Sagard debt is repaid ahead of schedule, and the buyback is executed, pushing the stock toward the upper analyst targets.
$50 to $65
More likely if Jemperli royalties keep growing at a high single-digit to double-digit pace, imsidolimab follows the expected regulatory path, Sagard paydown proceeds on schedule, and the stock stays between the 50-day and 200-day moving averages.
$30 to $45
More likely if Jemperli competition or pricing pressure slows sales growth, imsidolimab hits a regulatory delay or rejection, GSK litigation turns unfavorable, the buyback is not executed, or high short interest combines with a sector-wide sell-off.
ANAB AI technical analysis
ANAB AI technical analysis shows a stock that more than doubled over 52 weeks to a $73.30 high, then corrected about 23% to $53.66 as of the August 4, 2026 data cutoff. Price is below the 50-day moving average near $57.59 and slightly above the 200-day moving average near $52.82, a neutral-to-cautious setup. Volume spiked on down days in mid-July, and short interest is elevated near 17% of shares outstanding.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $53.66 | August 3, 2026 close, up 0.56% on the day, with after-hours at $53.72. Day range was $51.85 to $53.98. |
| 52-week high | $73.30 | The 52-week high marks the upper end of the range and a strong resistance zone after the mid-July sell-off. |
| Near support | $50 to $51 | The July 20 low of $50.29 and the July 28 low of $50.51 form the first pullback support zone. |
| Secondary support | $48 to $49 | The July 21 intraday low of $49.71 and round-number $48-49 levels mark the next support band. |
| Deep support | $44 to $45 | Round-number support near $45 would be the next major level if $48 fails. |
| Near resistance | $55 to $56 | The July 30 high of $55.29 and round-number $55-56 levels form the immediate resistance band. |
| Upper resistance | $58 to $59 | The July 17 high of $58.62 and the July 20 opening gap near $58.41 mark the next resistance zone. |
| Higher resistance | $62 to $63 | The July 14 close of $62.51 and the early July trading band near $62-65 represent stronger supply. |
| Moving averages | 50-day $57.59, 200-day $52.82 | Price below the 50-day average is short-term bearish; holding above the 200-day average keeps the intermediate trend intact. |
| Momentum | Neutral-to-weak, RSI near 44.5 | RSI near 44.5 is neutral to slightly weak, consistent with the pullback from the July high. |
| Volume | Average near 769K shares | 20-day average volume is about 769K shares. Down days in mid-July printed above-average volume, indicating distribution. |
| Volatility | Beta of 0.38, event volatility high | Low statistical beta masks event risk. Earnings, PDUFA decisions, GSK updates, and litigation news can move the stock sharply. |
| Invalidation | Close below $48, then below $45 | A close below $48 would break the secondary support and confirm a weaker short-term trend. A close below $45 would suggest a deeper correction. |
ANAB AI trading strategy
The ANAB AI trading strategy below is a rules-based research framework, not personal advice. It connects chart levels with Jemperli royalty momentum, imsidolimab PDUFA timing, the Sagard paydown schedule, buyback activity, and partner-related news flow.
A constructive setup requires a reclaim of the 50-day moving average near $57.59 with above-average volume, followed by a move through the $58-59 resistance zone toward $62-63. The 200-day average near $52.82 is the reference for the intermediate trend.
A close below $50 support should trigger a review. A close below $48 would break secondary support and reduce setup confidence.
Track the August 6, 2026 earnings date, the imsidolimab PDUFA date of December 12, 2026, AZUR-1 data expected in the second half of 2026, AZUR-4 data expected in Q4 2026, GSK litigation updates, and Sagard paydown progress. Positions held through binary events require defined loss tolerance.
With about 17% of shares sold short, squeeze-driven gaps can move both ways. Size positions for the possibility of double-digit moves on news and do not risk capital that cannot absorb event risk.
Monitor Jemperli quarterly sales growth reported by GSK, imsidolimab approval progress, collaboration revenue trends in AnaptysBio filings, cash and Sagard debt balances, the liability related to sale of future royalties, buyback execution, and analyst target changes.
This is a single-stream royalty stock whose value rests largely on GSK execution and the Sagard structure. Keep position sizing conservative and review the thesis after each quarterly filing.
Investment research summary
AnaptysBio earns money as a royalty management company. GSK sells Jemperli and pays AnaptysBio royalties, and Vanda develops imsidolimab with a royalty and milestone structure for AnaptysBio. Customers do not buy from AnaptysBio directly; value comes from the partner programs it manages.
The moat is indirect and moderate: long-dated collaboration agreements, the underlying intellectual property behind Jemperli and imsidolimab, and the difficulty of replicating the royalty streams. AnaptysBio does not control the commercial engine, which limits the strength of the moat.
The thesis fails if GSK Jemperli sales growth stalls or competition intensifies, imsidolimab is delayed or rejected at the December 2026 PDUFA date, the Sagard royalty monetization reduces future cash flow more than modeled, GSK litigation turns adverse, or the optional buyback is not executed.
Management executed a complex spin-off, built a lean virtual operating model with a guided EBIT margin above 95%, and recruited royalty-sector leaders including a former Royalty Pharma CFO. The $100 million buyback expires at the end of 2026 and is optional, so capital return is not yet proven.
Royalty financing and oncology checkpoint inhibitors like Jemperli remain commercially attractive areas, and imsidolimab targets a clear unmet need in generalized pustular psoriasis. The counter-trends are intensifying competition in PD-1 class therapies, payer pressure, and concentrated royalty-stream dependency.
ANAB trades at about 6.8x trailing revenue and 30.1x forward earnings with a thin book value and an EV near 44.8x EBITDA. The price already assumes continued Jemperli growth and imsidolimab approval, so there is limited earnings-based margin of safety and meaningful downside if partner execution disappoints.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Current price | $53.66 close on August 3, 2026, after-hours $53.72 | StockAnalysis.com ANAB quote | August 4, 2026 |
| Market capitalization | $1.59B, verified as $53.66 x 29.61M shares (0.07% deviation) | financial_rigor.py market cap verification | August 4, 2026 |
| TTM revenue | $232.39M (trailing twelve months, includes pre-spin activity) | StockAnalysis.com statistics | August 4, 2026 |
| TTM net income | -$26.79M, EPS -$0.95 | StockAnalysis.com statistics | August 4, 2026 |
| Cash and investments | $286.46M at March 31, 2026 | StockAnalysis.com balance sheet and Q1 2026 press release | August 4, 2026 |
| Total debt / net cash | $277.36M total debt; $9.10M net cash | StockAnalysis.com statistics | August 4, 2026 |
| Enterprise value | About $1.58B; EV/EBITDA about 44.8x | StockAnalysis.com statistics | August 4, 2026 |
| 52-week range | $17.11 to $73.30 | StockAnalysis.com quote and price history | August 4, 2026 |
| Beta (5Y monthly) | 0.38 | StockAnalysis.com statistics | August 4, 2026 |
| Price/Sales (TTM) and forward PE | P/S 6.84x; Forward PE 30.13x | StockAnalysis.com statistics | August 4, 2026 |
| Analyst consensus target | $87.09 average, $70 low, $140 high; Strong Buy from 11 analysts | StockAnalysis.com forecast | August 4, 2026 |
| FY2025 results | $234.60M revenue (+157%), operating income $47.90M, net loss -$13.23M | StockAnalysis.com financials | August 4, 2026 |
| Q1 2026 collaboration revenue | $25.56M, including $24.7M Jemperli royalties (+44% YoY) | AnaptysBio Q1 2026 earnings release | August 4, 2026 |
| Short interest | 5.00M shares, about 16.89% of shares outstanding and 24.83% of float | StockAnalysis.com statistics | August 4, 2026 |
This ANAB AI stock analysis is an informational research tool, not investment advice, a recommendation, or a promise of future returns. Forecast scenarios are based on available public data as of August 4, 2026 and may be wrong if Jemperli sales, imsidolimab approval timing, GSK litigation, Sagard debt repayment, buyback execution, financing conditions, or market sentiment changes.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
